2. Signaling Pathways
  3. GPCR/G Protein
  4. Amylin Receptor

Amylin Receptor

AMYR

Amylin receptors (AMYRs) are G protein-coupled receptors (GPCRs), which respond to the peptide hormones amylin and calcitonin. Amylin was originally discovered as the main constituent of pancreatic islet amyloid deposits in type 2 diabetics and in diabetic cats, amylin is also a physiologically relevant circulating peptide hormone. Amylin receptors are heterodimers comprising the calcitonin receptor, which is a G protein–coupled receptor, and one of three receptor-modifying proteins. An impediment to functional studies is that it is difficult to separate amylin receptor phenotypes from calcitonin receptor phenotypes. Amylin receptors are targets for treating obesity and metabolic disorders.

Amylin Receptor Related Products (54):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P11245
    NN1213
    		Agonist
    NN1213, a long-acting human amylin peptide analog, is a selective Amylin receptor agonist with EC50 values of 0.177 and 0.262 nM for hAMY3R and rAMY3R, respectively. NN1213 significantly reduces food intake and fat mass. NN1213 can reduce body weightin diet-induced obese rats. NN1213 can be used for the research of obesity.
    NN1213
  • HY-P1871
    Amylin (IAPP), feline
    Amylin (IAPP), feline is a 37-amino acid polypeptide from feline. Amylin (IAPP), feline is one of the major secretory products of β-cells of the pancreatic islets. Amylin (IAPP), feline is a regulatory peptide, which inhibits insulin and glucagon secretion.
    Amylin (IAPP), feline
  • HY-P991249
    NI-203
    		Inhibitor
    NI-203 is a monoclonal antibody inhibitor that targets amylin. NI-203 is promising for research of type 2 diabetes.
    NI-203
  • HY-P11587
    BGM1812
    		Agonist
    BGM1812 is a dual agonist of amylin (hAMY3R) (EC50 = 0.627 nM) and CGRP Receptor (hCTR) (EC50 = 2.27 nM). BGM1812 achieves weight loss, increases the proportion of lean body mass, and reduces fat mass in diet-induced obese (DIO) rats. BGM1812 is applicable to research related to obesity.
    BGM1812
  • HY-P0058A
    Pramlintide TFA
    Pramlintide TFA is a polypeptide analogue of human amylin. Pramlintide TFA, an antidiabetic agent, is antineoplastic in colorectal cancer.
    Pramlintide TFA
  • HY-P11588
    KBP-042
    		Activator
    KBP-042 is an orally active amylin receptor activator, a calcitonin receptor activator. KBP-042 induces sustained weight loss, reduces adipose tissue mass, lowers hepatic lipid deposition, increases plasma adiponectin, decreases plasma leptin, and reduces plasma glucose-dependent insulinotropic peptide levels. KBP-042 can be used for the research of obesity and insulin resistance.
    KBP-042
  • HY-182304
    CLR01 sodium
    CLR01 sodium is a blood-brain barrier-permeable anti-aggregation agent. CLR01 sodium inhibits the de novo aggregation of Amyloid-β 40/42, α-synuclein, IAPP, tau protein and SOD1. CLR01 sodium reduces amyloid plaque burden in the cortex of triple-transgenic mice and improves the memory and motor abilities of these mice. CLR01 sodium can be used in research related to Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS).
    CLR01 sodium
  • HY-180425
    Cloridarol
    		Inhibitor
    Cloridarol is a human islet amyloid peptide (hIAPP) inhibitor that prevents its abnormal misfolding and aggregation. Cloridarol can increase cell viability, inhibit apoptosis, and protect islet β-cells from hIAPP-induced cell toxicity. Cloridarol can be used for the research of type 2 diabetes (T2D).
    Cloridarol
  • HY-P11629
    KBP-336
    		Agonist
    KBP-336 is a dual amylin and calcitonin receptor agonist (DACRA). KBP-336 exhibits antidiabetic and insulin-sensitizing properties, improves glucose levels, spatial learning, and memory in diabetic rats, and reduces blood glucose. KBP-336 also alleviates pain-like symptoms in osteoarthritis rats. KBP-336 also promotes weight and fat reduction. KBP-336 is useful for research on diabetes, obesity, and arthritis.
    KBP-336
  • HY-185229A
    CTR/AMYR agonist-1 enantiomer
    		Agonist
    CTR/AMYR agonist-1 enantiomer is an enantiomer of CTR/AMYR agonist-1 (HY-185229). CTR/AMYR agonist-1 is a CTR/AMYR agonist with EC50 values of 0.56-6.9 nM. CTR/AMYR agonist-1 can be used for the research of metabolic disease.
    CTR/AMYR agonist-1 enantiomer
  • HY-185234
    CTR/AMYR activator-1
    		Activator
    CTR/AMYR activator-1 (S configuration of compound 122) is a CTR/AMYR activator. CTR/AMYR activator-1 can be used in the research of bone diseases, metabolic diseases, cardiovascular diseases, and neurodegenerative diseases.
    CTR/AMYR activator-1
  • HY-P0058S
    Pramlintide-(Ala-13C3,15N)
    Pramlintide-(Ala-13C3,15N) is the 13C- and 15N-labeled Pramlintide. Pramlintide is a polypeptide analogue of human amylin. Pramlintide, an antidiabetic agent, is antineoplastic in colorectal cancer.
    Pramlintide-(Ala-<sup>13</sup>C<sub>3</sub>,<sup>15</sup>N)
  • HY-185229
    CTR/AMYR agonist-1
    		Agonist
    CTR/AMYR agonist-1 is a CTR/AMYR agonist with EC50 values of 0.56-6.9 nM. CTR/AMYR agonist-1 can be used for the research of metabolic disease.
    CTR/AMYR agonist-1
  • HY-179728
    Amylin agonist 1
    		Agonist
    Amylin agonist 1 (Example 239a) is a receptor 3 for pancreatic amyloid peptide (bAMY3R) agonist, and its EC50 for stimulating cAMP production in cells is 6.17 nM. Amylin agonist 1 is also a receptor for calcitonin (bCTR) agonist, with its EC50 being 8.58 nM. Amylin agonist 1 can be used for research on type 2 diabetes and obesity.
    Amylin agonist 1